(TRVI) Trevi Therapeutics - Overview
Stock: Chronic Cough, IPF, Refractory Cough, Pruritus, Prurigo Nodularis
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 72.3% |
| Relative Tail Risk | -12.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.62 |
| Alpha | 164.42 |
| Character TTM | |
|---|---|
| Beta | 0.319 |
| Beta Downside | -0.326 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.04% |
| CAGR/Max DD | 0.98 |
Description: TRVI Trevi Therapeutics January 21, 2026
Trevi Therapeutics, Inc. (NASDAQ: TRVI) is a clinical-stage biopharma focused on oral nalbuphine-based products for chronic cough associated with idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases, as well as refractory cough and pruritus conditions. Its lead candidate, Haduvio (extended-release nalbuphine), is currently in a Phase 2b trial for cough reduction in IPF patients, a Phase 2 trial for pruritus, and a combined Phase 2b/3 study for prurigo nodularis. The company operates under a license with Endo Pharmaceuticals to develop and commercialize nalbuphine formulations.
Key quantitative points (as of the most recent 10-Q): cash and cash equivalents of roughly $55 million, a monthly burn rate of about $2.5 million, and a runway extending into Q4 2025 assuming no additional financing. The IPF market in the U.S. is estimated at $1.2 billion annually, with chronic cough representing a high-unmet-need segment that could support a niche product priced in the $10-15 k per patient range. A positive readout from the Phase 2b IPF cough trial, expected in H2 2026, would be a primary catalyst for share price volatility.
Sector-wide drivers that affect Trevi include the broader biotech financing environment (U.S. venture capital inflows to early-stage therapeutics were $12 billion in 2023, down 8 % YoY) and FDA regulatory trends favoring accelerated pathways for orphan respiratory indications, which could shorten time-to-market if the data meet efficacy thresholds.
If you’re looking for a deeper, data-centric view of TRVI’s risk-reward profile, ValueRay’s analyst toolkit offers a concise dashboard worth exploring.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -45.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.22 > 0.02 and ΔFCF/TA 28.87 > 1.0 |
| NWC/Revenue: 129.6k% < 20% (prev 33.1k%; Δ 96.6k% < -1%) |
| CFO/TA -0.22 > 3% & CFO -44.0m > Net Income -45.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 21.93 > 1.5 & < 3 |
| Outstanding Shares: last quarter (145.1m) vs 12m ago 43.61% < -2% |
| Gross Margin: 22.60% > 18% (prev 0.18%; Δ 2242 % > 0.5%) |
| Asset Turnover: 0.11% > 50% (prev 0.26%; Δ -0.15% > 0%) |
| Interest Coverage Ratio: -45.9k > 6 (EBITDA TTM -45.7m / Interest Expense TTM 1000 ) |
Altman Z'' -15.00
| A: 0.95 (Total Current Assets 198.3m - Total Current Liabilities 9.04m) / Total Assets 199.4m |
| B: -1.61 (Retained Earnings -321.5m / Total Assets 199.4m) |
| C: -0.34 (EBIT TTM -45.9m / Avg Total Assets 134.1m) |
| D: -33.58 (Book Value of Equity -321.3m / Total Liabilities 9.57m) |
| Altman-Z'' Score: -36.59 = D |
What is the price of TRVI shares?
Over the past week, the price has changed by +9.46%, over one month by +4.37%, over three months by +4.09% and over the past year by +169.01%.
Is TRVI a buy, sell or hold?
- StrongBuy: 7
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the TRVI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 21.3 | 85.9% |
| Analysts Target Price | 21.3 | 85.9% |
| ValueRay Target Price | 16.9 | 47.2% |
TRVI Fundamental Data Overview February 02, 2026
Revenue TTM = 146.0k USD
EBIT TTM = -45.9m USD
EBITDA TTM = -45.7m USD
Long Term Debt = 823.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 296.0k USD (from shortTermDebt, last quarter)
Debt = 823.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -56.0m USD (from netDebt column, last quarter)
Enterprise Value = 1.15b USD (1.34b + Debt 823.0k - CCE 194.9m)
Interest Coverage Ratio = -45.9k (Ebit TTM -45.9m / Interest Expense TTM 1000 )
EV/FCF = -26.09x (Enterprise Value 1.15b / FCF TTM -44.0m)
FCF Yield = -3.83% (FCF TTM -44.0m / Enterprise Value 1.15b)
FCF Margin = -30.2k% (FCF TTM -44.0m / Revenue TTM 146.0k)
Net Margin = -31.4k% (Net Income TTM -45.9m / Revenue TTM 146.0k)
Gross Margin = 22.60% ((Revenue TTM 146.0k - Cost of Revenue TTM 113.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 5.76 (Enterprise Value 1.15b / Total Assets 199.4m)
Interest Expense / Debt = 0.12% (Interest Expense 1000 / Debt 823.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -36.3m (EBIT -45.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 21.93 (Total Current Assets 198.3m / Total Current Liabilities 9.04m)
Debt / Equity = 0.00 (Debt 823.0k / totalStockholderEquity, last quarter 189.8m)
Debt / EBITDA = 1.23 (negative EBITDA) (Net Debt -56.0m / EBITDA -45.7m)
Debt / FCF = 1.27 (negative FCF - burning cash) (Net Debt -56.0m / FCF TTM -44.0m)
Total Stockholder Equity = 146.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -34.19% (Net Income -45.9m / Total Assets 199.4m)
RoE = -31.23% (Net Income TTM -45.9m / Total Stockholder Equity 146.8m)
RoCE = -31.08% (EBIT -45.9m / Capital Employed (Equity 146.8m + L.T.Debt 823.0k))
RoIC = -24.69% (negative operating profit) (NOPAT -36.3m / Invested Capital 146.8m)
WACC = 7.09% (E(1.34b)/V(1.34b) * Re(7.09%) + D(823.0k)/V(1.34b) * Rd(0.12%) * (1-Tc(0.21)))
Discount Rate = 7.09% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 20.77%
Fair Price DCF = unknown (Cash Flow -44.0m)
EPS Correlation: 50.22 | EPS CAGR: 142.4% | SUE: 4.0 | # QB: 3
Revenue Correlation: 18.89 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.12 | Chg30d=+0.009 | Revisions Net=+1 | Analysts=5
EPS next Year (2026-12-31): EPS=-0.47 | Chg30d=-0.010 | Revisions Net=+4 | Growth EPS=-27.0% | Growth Revenue=+0.0%